导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.06% | 2207/4773 |
| 近一周 | -1.58% | 550/5462 |
| 近一月 | -1.49% | 965/5421 |
| 近一季 | -4.88% | 1721/5209 |
| 近半年 | -10.73% | 3672/4920 |
| 近一年 | 2.92% | 2029/4366 |
| 近两年 | 26.51% | 2431/2954 |
| 近三年 | 17.72% | 1562/2253 |
| 成立以来 | 90.82% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.23% 778/4961 |
1.24% 3057/5312 |
- - |
- - |
| 2025 | 6.39% 2965/4813 |
-4.23% 3145/3635 |
0.92% 2529/4076 |
6.85% 3501/4524 |
3.02% 781/4813 |
| 2024 | 17.58% 675/3463 |
9.07% 149/2808 |
1.94% 426/3014 |
6.17% 2867/3129 |
-0.40% 1411/3463 |
| 2023 | 7.11% 152/2656 |
15.64% 209/2280 |
0.84% 271/2385 |
-3.06% 840/2515 |
-5.24% 1299/2655 |
| 2022 | -11.90% 263/2207 |
-10.33% 392/1919 |
2.46% 1299/2016 |
-9.20% 256/2113 |
5.60% 455/2208 |
| 2021 | 28.35% 83/1822 |
3.50% 174/1255 |
4.62% 863/1330 |
16.90% 70/1466 |
1.40% 946/1822 |
| 2020 | 12.38% 811/1250 |
-7.99% 584/1028 |
-0.12% 1013/1067 |
11.02% 487/1164 |
10.14% 613/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 富国中证央企创新驱动ETF联接C VS. 长安沪深300非周期A(740101) |